These findings reveal a PLK1-FBW7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with BCL-2 antagonists, as potential effective therapeutics for Myc-overexpressing cancers.54 This evidence concerns the gene MYC and cancer.